Elegance clinical study it was reported than an embolism occurred.The subject underwent treatment with the ranger drug coated balloon on (b)(6)2023 as a part of the elegance clinical trial.The target lesion was in right distal superficial femoral artery (sfa) with 5 mm proximal reference vessel diameter and 5 mm distal reference vessel diameter with lesion length of 400 mm and 70% stenosis and was classified as tasc ii c lesion.Prior to target lesion treatment with study device, atherectomy was performed using 5 mm x 200 mm jetstream 2.4/3.4 atherectomy device.Treatment of target lesion was performed by dilation using study device, 5 mm x 150 mm ranger drug coated balloon.Post treatment, the final residual stenosis was noted to be 5%.On (b)(6)2023, on the same day of index procedure, during the treatment of the target lesion, embolism was noted in the right popliteal artery due to 5 mm x 200 mm jetstream 2.4/3.4 atherectomy device.As a response to the complication, balloon dilation and cdt urokinase were performed.Post treatment, the final residual stenosis was noted to be 5%.The complication of embolism was resolved.On (b)(6) 2023, the subject was discharged on clopidogrel.
|